Clinical Trial Update: Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating capecitabine in metastatic prostate cancer unresponsive to hormone therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED